New flu vaccine for seniors passes first safety check

NCT ID NCT07421050

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing whether a new flu vaccine with an adjuvant (a booster ingredient) is safe for adults aged 65 and older. Eighty volunteers will receive a single shot and be monitored for side effects over a year. The study does not yet test if the vaccine prevents flu, only its safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Subunit Influenza Vaccine (Adjuvant)

What this could lead to

If this vaccine is found safe, it could lead to a better flu shot for older adults, who are at higher risk of severe flu.

What could go wrong

This is a very early Phase 1 trial with only 80 people, so it can't prove the vaccine works. It only checks for immediate safety issues.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLUENZA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

influenza prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Gucheng County Center for Disease Control and Prevention

    Xiangyang, Hubei, China